Huijian Zheng

Fujian Provincial Key Laboratory On Hematology, Fujian Medical University Union Hospital
Fuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity.

Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity.

Journal: Frontiers in medicine

Published: August 17, 2025

Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.

Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: August 14, 2025

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.

Journal: Journal of hematology & oncology

Published: December 19, 2024

Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.

Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.

Journal: Scientific reports

Published: July 21, 2024

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.

Journal: Discover oncology

Published: April 14, 2023

Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia.

Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia.

Journal: Cell death & disease

Published: February 08, 2023

Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia.

Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia.

Journal: Frontiers in immunology

Published: January 07, 2023

Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.

Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.

Journal: Journal of cancer research and clinical oncology

Published: September 21, 2022

Microfluidic chip with reversible interface for noninvasive remission status monitoring and prognosis prediction of acute myeloid leukemia.

Microfluidic chip with reversible interface for noninvasive remission status monitoring and prognosis prediction of acute myeloid leukemia.

Journal: Biosensors & bioelectronics

Published: July 12, 2022

Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.

Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.

Journal: Journal of hematology & oncology

Published: May 11, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026